Patients with CC treated by postoperative VMAT in the author's hospital from 2018
to 2021 were retrospectively reviewed and enrolled in this study. Patients were
immobilized in the supine position with a thermoplastic abdominal fixation
device and simulated using a 16-slice Brilliance Big Bore CT scanner (Philips
Healthcare) at continuous 3-mm slices. The clinical target volume (CTV) of each
patient was contoured by a resident radiation oncologist and then reviewed,
edited, and finally approved by a senior radiation oncologist according to the
consensus guideline.2 (link) The corresponding planning target volume (PTV) was
generated with a 3-dimensional margin of 5 mm around the CTV. VMAT plans were
optimized and calculated with a dose calculation grid of 3 mm in the Monaco
treatment planning system (TPS) version 5.1.03 (Elekta) with a dose prescription
of 50Gy for 25 fractions or 45Gy for 25 fractions to the PTV, as reported in the
previous study.25 (link) The reporting of this study conforms to STROBE
guidelines.26 (link) As for the simulation nature of this retrospective
study, the ethical approval was waived by the ethical committee of authors’
hospital.